Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6

Blood

Volumn 95, Issue 12, 2000, Pages 3765-3770

  Schuringa, Jan Jacob ^b   Wierenga, Albertus T J ^b   Kruijer, Wiebe ^b   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MESSENGER RNA; PROTEIN; SERINE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TYROSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA BINDING; ELECTROPHORETIC MOBILITY; HEMATOPOIESIS; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 0034660463     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3765     Document Type: Article

References (59)

1. Vellenga E, Griffin JD. The biology of acute myeloblastic leukemia. Semin Oncol. 1987;14:365-371.
2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278: 1059-1064.
3. Rabbitts TH. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell. 1991;67:641-644.
4. Rabbirts TH. Chromosomal translocations in human cancer. Nature. 1994;372:143-149.
5. Solomon E, Borrow J, Goddard AD. Chromosome aberrations and cancer. Science. 1991;254:1153-1160.
6. Dokter WH, Tuyt L, Sierdsema SJ, Esselink MT, Vellenga E. The spontaneous expression of interleukin-1 beta and interleukin-6 is associated with spontaneous expression of AP-1 and NF-kappa B transcription factor in acute myeloblastic leukemia cells. Leukemia. 1995;9:425-432.
7. Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science. 1993;260:1808-1810.
8. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell. 1989;58:573-581.
9. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/ IFN beta 2) receptor. Science. 1988;241:825-828.
10. Gearing DP, Comeau MR, Friend DJ, et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science. 1992;255:1434-1437.
11. Ip NY, Nye SH, Boulton TG, et al. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell. 1992;69:1121-1132.
12. Yin T, Taga T, Tsang ML, Yasukawa K, Kishimoto T, Yang YC. Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol. 1993;151:2555-2561.
13. Schindler C, Darnell JEJ. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621-651.
14. Wen Z, Zhong Z, Darnell JEJ. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995; 82:241-250.
15. Wen Z, Darnell JEJ. Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stall and Stat3. Nucl Acids Res. 1997;25:2062-2067.
16. Schuringa JJ, Jonk LJC, Dokter WHA, Vellenga E, Kruijer W. IL-6 induced STAT3 transactivation and Serine 727 phosphorylation involves Vav, Rac, and SEK/MKK-4 as signal transduction components. Biochem J. 2000;347:89-96.
17. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921-924.
18. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-929.
19. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921.
20. Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A. 1998;95:114-119.
21. Nicholson SE, Willson TA, Parley A, et al. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 1999;18:375-385.
22. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. 1998;273: 35,056-35,062.
23. Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. Bioessays. 1999;21:47-52.
24. Cao X, Tay A, Guy GR, Tan YH. Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol. 1996;16:1595-1603.
25. Tuyt LML, Bregman K, Lummen C, Dokter WH, Vellenga E. Differential binding activity of the transcription factor LIL-STAT in immature and differentiated normal and leukemia myeloid cells. Blood. 1998;92:1364-1373.
26. Turkson J, Bowman T, Garcia R, Caldenhoven E, De-Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18:2545-2552.
27. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by the v-abl oncogene. Science. 1995;269:1875-1877.
28. Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997;8:1267-1276.
29. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosme kinase signaling. J Biomed Sci. 1998;5:79-85.
30. Migone TS, Lin JX, Cereseto A, et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269:79-81.
31. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DMA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;69:81-83.
32. Zong C, Yan R, August A, Darnell JEJ, Hanafusa H. Unique signal transduction of Eyk: constitutive stimulation of the JAK-STAT pathway by an oncogenic receptor-type tyrosine kinase. EMBO J. 1996;15:4515-4525.
33. Gouilleux GV, Gouilleux F, Desaint C, et al. STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood. 1996;87:1692-1697.
34. Gouilleux GV, Debierre GF, Gouilleux F, et al. Activated Stat related transcription factors in acute leukemia. Leuk Lymphoma. 1997;28:83-88.
35. Xia Z, Baer MR, Block AW, Baumann H, Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res. 1998;58:3173-3180.
36. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100:3140-3148.
37. Fukada T, Ohtani T, Yoshida Y, et al. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 1998;17:6670-6677.
38. Benett JM, Catovski D, Daniel MT, et al. Proposal for the classification of the acute leukemia (FAB cooperation group). Br J Haematol. 1976;33:451.
39. Wagteveld AJ, Esselink MT, Limburg P, Halie MR, Vellenga E. The effects of IL-1 beta and IL-4 on the proliferation and endogenous secretion of growth factors by acute myeloblastic leukemic cells. Leukemia. 1992;6:1020-1024.
40. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells. Nucl Acids Res. 1989;17:6419.
41. Griffin JD, Rambaldi A, Vellenga E, Young DC, Ostapovicz D, Cannistra SA. Secretion of interleukm-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood. 1987;70:1218-1221.
42. Van-Damme J, Opdenakker G, Simpson RJ, et al. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/ plasmacyloma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med. 1987; 165;914-919.
43. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998;16:249-284.
44. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 1994;368:339-342.
45. Jansen JH, Kluin NJ, Van-Damme J, Wientjens GJ, Willemze R, Fibbe WE. Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells. J Exp Med. 1992;175:1151-1154.
46. Kimura H, Ishibashi T, Uchida T, Maruyama Y, Friese P, Burstein SA. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol. 1990;20:1927-1931.
47. Asano S, Okano A, Ozawa K, et al. In vivo effects of recombinant human interleukin-6 in primates: stimulated production of platelets. Blood. 1990: 75:1602-1605.
48. Pojda Z, Tsuboi A. In vivo effects of human recombinant interleukin 6 on hemopoietic stem and progenitor cells and circulating blood cells in normal mice. Exp Hematol. 1990;18:1034-1037.
49. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 1996;15:3651-3658.
50. Akashi K, Harada M, Shibuya T, et al. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34-blasts from acute myelogenous leukemia. Blood. 1991;78:197-204.
51. Koistinen P, Saily M, Poromaa N, Savolainen ER. Complex effects of interleukin 6 on clonogenic blast cell growth in acute myeloblastic leukemia. Acta Haematol. 1997;98:14-21.
52. School van der CE, Jansen P, Poorter M, et al. Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. Blood. 1989;74:2081-2087.
53. Hoang T, Haman A, Goncalves O, Wong GG, Clark, SC. Interleukin-6 enhances growth factor-dependent proliferation of the blast cells of acute myeloblastic leukemia. Blood. 1988;72:823-826.
54. Saily M, Koistinen P, Savolainen ER. The soluble form of interleukin-6 receptor modulates cell proliferation by acute myeloblastic leukemia blast cells. Ann Hematol. 1999;78:173-179.
55. Curtis DJ, Metcalf D, Alexander B, Begley CG. Leukemic cells from murine myeloid leukemia display an intrinsic ability for autonomous proliferation. Exp Hematol. 2000;28:36-45.
56. Catlett FR, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
57. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98:295-303.
58. Tuyt LM, de-Wit H, Koopmans SB, Sierdsema SJ, Vellenga E. Effects of IL-3 and LPS on transcription factors involved in the regulation of IL-6 mRNA. Br J Haematol. 1996;92:521-529.
59. Tuyt LM, Dokter WH, Birkenkamp K, et al. Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J Immunol. 1999;162:4893-4902.